Liquid Biopsy in Lung and Breast Cancer: Real World Tumour Profiling and Clinical Insights
Liquid biopsy is increasingly being adopted to support tumour profiling across cancer pathways, particularly where tissue is limited or results are needed quickly.
Clinical Scorecard: Liquid Biopsy in Lung and Breast Cancer: Real World Tumour Profiling and Clinical Insights
At a Glance
Category Detail
Condition Lung and Breast Cancer Key Mechanisms Liquid biopsy comprehensive genomic profiling (CGP) complements tissue testing. Target Population Patients with lung and breast cancer. Care Setting Clinical settings integrating liquid biopsy into cancer pathways.
Key Highlights
Introduction to liquid biopsy CGP and its role in cancer diagnostics. Integration of liquid biopsy into lung cancer pathways. Use of ESR1 testing in blood samples from breast cancer patients. Support for faster, informed treatment decision making. Real-world implementation insights from Wales. Guideline-Based Recommendations
Diagnosis
Utilize liquid biopsy CGP alongside traditional tissue testing. Management
Incorporate earlier molecular insights for treatment decisions. Monitoring & Follow-up
Regularly assess the integration of liquid biopsy in clinical workflows. Risks
Address operational and clinical challenges during liquid biopsy adoption. Patient & Prescribing Data
Patients undergoing treatment for lung and breast cancer.
Liquid biopsy can provide timely molecular insights to guide therapy.
Clinical Best Practices
Ensure comprehensive training for staff on liquid biopsy workflows. Implement strategies to overcome challenges in liquid biopsy adoption. Regularly evaluate the clinical value of liquid biopsy in patient management. References
